Effect of Cumulative Dose of Brentuximab Vedotin Maintenance in Relapsed/Refractory Classical Hodgkin Lymphoma after Autologous Stem Cell Transplant: An Analysis of Real-World Outcomes

Data were collected from patients who received at least one cycle of brentuximab vedotin maintenance after autologous stem cell transplant with primary refractory disease, extra-nodal disease, or relapse < 12 months from the end of frontline therapy.